Global Myelodysplastic Syndrome Drugs Market by Therapeutic Class (Anti-anemics, Immunomodulatory Drugs, Hypomethylating Agents) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global myelodysplastic disorder (MDS) drugs market was valued at USD1.3 billion in 2016. It is expected to grow 9.7% during the forecast period. The emergence of new therapeutics is the main driver of this market. The market will be driven by the rising geriatric population, the increasing incidence of niche indications and improved healthcare services.

Myelodysplastic Syndrome is caused by mutations in one or more genes that regulate the development of blood cells. It is the most common malignant hematological disease and affects 5 out of 100,000 Americans annually. MDS affects approximately 60,000 Americans. Each year, between 10,000 and 15,000 new cases are reported. There may be clinical manifestations like anemia, neutropenia, or thrombocytopenia. Disease onset may be triggered by exposure to chemicals such as pesticides and tobacco.

The approval and adoption by Vidaza and Dacogen has led to a rise in demand for hypomethylating agent. Market growth will be boosted by a strong pipeline that includes Aranesp. Strong commercial opportunities are available for the market due to its easy availability and access of novel treatments in large countries.

This market is driven by the aging population and increasing awareness of the disease. Market growth is expected to be fueled by government initiatives to offer targeted treatments and favorable reimbursement policies. MDS International Foundation, a non-profit health organization, provides financial support and psychological support to patients afflicted by the condition.

The high cost of therapeutics continues to be a barrier to the growth in the market for drugs with myelodysplastic syndrome. Affordable healthcare measures are being implemented in all major markets. This has an impact on companies' pricing strategies as well as the reimbursement scenario. Additionally, companies will be less likely to offer premium pricing strategies due to rising costs.

Because of the complexity and heterogeneity involved in MDS, it is difficult to develop novel treatments. Although effective, most of the available treatment options provide only symptomatic relief. The only treatment for myelodysplastic is stem cell transplant. However, this comes with higher risks and may not be available to patients who have other medical conditions.

Therapeutic Class Insights

MDS drugs can be divided into three therapeutic classes: anti-anemics, hypomethylating agents, and immunomodulatory drugs. In 2016, immunomodulatory drugs occupied the largest market share. They are expected to continue their dominance into 2022, due to increased adoption of therapeutics as well as a lack of generic competition. Revlimid (lenalidomide), currently the only approved treatment for low-risk MDS or myelodysplastic disorder with isolated del(5q) is available.

Patients with high-risk myelodysplastic disorder are treated first-line by hypomethylating agents like Celgene's Vidaza or Otsuka’s Dacogen. Market share in this segment is expected to drop sharply due to expiration of patents for both of the above-mentioned drugs. This has resulted in several generics being launched in the market.

Anti-anemics drugs will be boosted by the anticipated launches of Celgene’s luspatercept in 2019 and Amgen’s Aranesp. Both drugs are currently being tested in clinical trials to treat myelodysplastic disorder. Recent research has shown that both treatments increased RBC counts in blood and reduced the need for blood transfusions.

Country Insights

With a market share of over 48.0%, the United States dominated global myelodysplastic disorder treatment drugs market in 2016. Japan and Germany were close behind. Japan will show the highest CAGR, at nearly 13.0%, among the seven major markets. However, the U.S. will continue to hold its dominant position during the forecast period.

Its dominance is due to multiple product launches, increased adoption and use of novel therapies, large numbers of patients, and high costs of treatment in the U.S. The seven largest markets will grow at 9.4% each, while the Rest of the World will see a 12.1% CAGR during the forecast period.

Market Share insights for Myelodysplastic Syndrome (MDS).

Celgene and Otsuka are some of the major players in the market. Celgene was the market leader in MDS sales in 2016, thanks to strong Revlimid/Viaza sales, and it is expected that it will continue its dominance through 2022.

The forecast period will see significant revenue generation from Amgen’s Aranesp and Celgene’s luspatercept, Jazz’s Vyxeos as well as Otsuka’s guadecitabine and Takeda’s pevonedistat. Market leaders are expected to identify new targets and address unmet market needs, and develop better pipeline candidates.

Myelodysplastic Syndrome (MDS), Drugs Market Report Scope

The Report Covers Certain Segments

This report provides a forecast of revenue growth at the global, regional and country level and an analysis of industry trends in each sub-segment from 2016-2022. Grand View Research, Inc. analyzed the global myelodysplastic disorder (MDS), Drugs/Therapeutics Market Report based on therapeutic category and country.

• Therapeutic Class Outlook (Revenue USD Million, 2016-2022)

  • Hypomethylating Agents

  • Immunomodulatory Drugs

  • Anti-anemics

• Country Outlook (Revenue USD Million, 2016-2022)

  • The U.S.

  • The U.K.

  • Germany

  • Spain

  • Italy

  • France

  • Japan

These are the most frequently asked questions about this report

b. Global myelodysplastic Syndrome market was valued at USD 1.5 billion in 2019, and is projected to grow to USD 1.7 billion by 2020.

b. Global myelodysplastic Syndrome market is expected grow at a compound annual rate of 9.7% between 2016 and 2022, to reach USD 2.42 billion by 2022.

b. With a 64.3% share in 2019, immunomodulatory drugs dominated myelodysplastic disorder market. This is due to the rising popularity of immunomodulatory drugs as well as the lack of generic competition.

b. Celgene Corporation, Amgen Inc., Otsuka Pharmaceutical Co. Ltd. and Takeda Pharmaceutical Company Limited are some of the key players in the myelodysplastic Syndrome market.

b. Market growth is being driven by the development of new therapeutics, increased awareness about myelodysplastic disorder, and increasing R&D investments.

Up Market Research published a new report titled “Myelodysplastic Syndrome Drugs Market research report which is segmented by Therapeutic Class (Anti-anemics, Immunomodulatory Drugs, Hypomethylating Agents), By Players/Companies Celgene Corporation; Amgen Inc; Otsuka Pharmaceutical Co, Ltd; and Takeda Pharmaceutical Company Limited”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Myelodysplastic Syndrome Drugs Market Report Segments:

The market is segmented by Therapeutic Class (Anti-anemics, Immunomodulatory Drugs, Hypomethylating Agents).

Myelodysplastic Syndrome Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Myelodysplastic Syndrome Drugs Market

Overview of the regional outlook of the Myelodysplastic Syndrome Drugs Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Myelodysplastic Syndrome Drugs Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Myelodysplastic Syndrome Drugs Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Anti-anemics

                2. Immunomodulatory Drugs

                3. Hypomethylating Agents

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Myelodysplastic Syndrome Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Myelodysplastic Syndrome Drugs Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.